A Look at Revvity's Upcoming Earnings Report
Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Revvity to report an earnings per share (EPS) of $1.57.
The announcement from Revvity is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Overview of Past Earnings
The company's EPS beat by $0.04 in the last quarter, leading to a 0.73% drop in the share price on the following day.
Here's a look at Revvity's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.14 | 1.14 | 0.95 | 1.38 |
| EPS Actual | 1.18 | 1.18 | 1.01 | 1.42 |
| Price Change % | -1.00 | -1.00 | 0.00 | -1.00 |
Tracking Revvity's Stock Performance
Shares of Revvity were trading at $108.49 as of January 29. Over the last 52-week period, shares are down 12.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analyst Observations about Revvity
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Revvity.
Analysts have provided Revvity with 3 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $109.0, suggesting a potential 0.47% upside.
Understanding Analyst Ratings Among Peers
The following analysis focuses on the analyst ratings and average 1-year price targets of Qiagen, Tempus AI and Charles River, three prominent industry players, providing insights into their relative performance expectations and market positioning.
- Analysts currently favor an Neutral trajectory for Qiagen, with an average 1-year price target of $53.0, suggesting a potential 51.15% downside.
- Analysts currently favor an Buy trajectory for Tempus AI, with an average 1-year price target of $89.0, suggesting a potential 17.96% downside.
- Analysts currently favor an Neutral trajectory for Charles River, with an average 1-year price target of $208.6, suggesting a potential 92.28% upside.
Summary of Peers Analysis
The peer analysis summary outlines pivotal metrics for Qiagen, Tempus AI and Charles River, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Revvity | Neutral | 2.18% | $374.60M | 0.62% |
| Qiagen | Neutral | 6.12% | $331.26M | 3.64% |
| Tempus AI | Buy | 84.72% | $209.94M | -19.57% |
| Charles River | Neutral | -0.49% | $338.79M | 1.61% |
Key Takeaway:
Revvity ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.
All You Need to Know About Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Financial Insights: Revvity
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Revvity's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 2.18%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Revvity's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.67%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Revvity's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.62%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Revvity's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Revvity's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.46.
To track all earnings releases for Revvity visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.